DiaMedica Q2 net loss widen less than expected

DiaMedica Therapeutics

10/08/2026 21:39

Overview
US biopharma firm's Q2 net loss and loss per share beat analyst expectations
Company ended Q2 with $43.5 mln in cash and investments, runway expected through 2027
Higher R&D expenses reflect expansion of clinical trials for preeclampsia and stroke

Outlook
Company expects cash runway to fund operations and studies through 2027
DiaMedica anticipates R&D expenses to increase moderately as clinical programs expand
G&A expenses expected to remain steady compared to recent periods

Result Drivers
R&D EXPANSION - Higher research and development expenses driven by expanded clinical trials for preeclampsia, fetal growth restriction, and stroke
PIPELINE PROGRESS - Positive topline results in Phase 2 preeclampsia trial and completion of first fetal growth restriction cohort highlighted as key milestones
G&A COSTS - Slight increase in general and administrative expenses due to higher share-based compensation and professional fees

Company press release: ID:nBw6nZkq7a

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
Beat
$0.19
$0.20 (4 Analysts)
Q2 Net Loss
Beat
$10.14 mln
$10.82 mln (3 Analysts)
Q2 Operating Income
Beat
-$10.50 mln
-$11.10 mln (3 Analysts)
Q2 Cash & Investments
 
$43.5 mln
 
Q2 Pretax Loss
 
$10.13 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for DiaMedica Therapeutics Inc is $13.00, about 92.6% above its August 7 closing price of $6.75

Reuters Recommended Reads
Aug 10 - Olema Pharmaceuticals Q2 net loss widens on higher clinical trial spending
Aug 10 - Metagenomi Q2 net loss widens cash runway seen through 2027
Aug 10 - Palisade Bio Q2 net loss widens on higher R&D costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)